TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03766815

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA 200mg/kg/day
Description: BCAA supplement based on 200mg/kg/day for 18 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fiber supplement jelly for 18 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA 400mg/kg/day
Description: BCAA supplement based on 400mg/kg/day for 18 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle damaging exercise
Description: Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle damaging exercise
Description: Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Muscle damaging exercise
Description: Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.
Study: NCT04030208

Intervention type: DEVICE
Group type: OTHER
Intervention: Umbulizer
Description: Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Umbulizer
Description: Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional Mechanical Ventilator
Description: A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional Mechanical Ventilator
Description: A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.
Study: NCT02501928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 4 mg
Description: Fesoterodine 4 mg tablet once daily for 28 or 40 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 8 mg
Description: Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine BIC 2 mg
Description: Fesoterodine BIC 2 mg tablet once daily for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine BIC 4 mg
Description: Fesoterodine BIC 4 mg tablet once daily for 28 weeks
Study: NCT04445831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-35.030
Description: Administration of a Low dose of ACI-35.030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-35.030
Description: Administration of a Medium dose of ACI-35.030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-35.030
Description: Administration of a High dose of ACI-35.030

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JACI-35.054
Description: Administration of a Low dose of JACI-35.054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JACI-35.054
Description: Administration of a Medium dose of JACI-35.054
Study: NCT02836925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir+Sofosbuvir
Description: Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg~* 12 weeks in previously untreated infected patients~* 24 weeks for previously treated patients with uncertain subsequent retreatment options

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir+Velpatasvir
Description: Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg~· 12 weeks of treatment
Study: NCT01007305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral salpingo-oophorectomy
Description: Removal of both ovaries and fallopian tubes at the time of hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian conservation
Description: Both ovaries and fallopian tubes not removed at the time of hysterectomy
Study: NCT03719625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
Study: NCT03454503

Intervention type: DRUG
Intervention: Imatinib
Description: Film coated tablet contains 400 mg imatinib (as mesilate)

Intervention type: DRUG
Intervention: Imatinib
Description: Film coated tablet contains 400 mg imatinib (as mesilate)
Study: NCT02480101

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 live influenza vaccine
Description: H7N9 live influenza vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized purified allantoic fluid of chicken embryos with stabilizers
Study: NCT03583307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
Study: NCT03068741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison 2: Liberal fluids
Description: Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
Study: NCT02370238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
Study: NCT00512122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withholding PN during the first week of ICU stay
Description: Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E
Description: PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
Study: NCT01867892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT
Description: oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT
Description: Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
Study: NCT03068741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison 2: Conservative fluids
Description: Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is \<90mmHg and continued until systolic blood pressure is \>=100mmHg.
Study: NCT01113593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Inhalation solution
Study: NCT01860274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Mesh for vein grafts
Study: NCT03478722

Intervention type: OTHER
Intervention: Protein Meal
Description: Ingestion of mixed meal containing 20 g of dietary protein

Intervention type: OTHER
Intervention: Protein Meal
Description: Ingestion of mixed meal containing 20 g of dietary protein

Intervention type: OTHER
Intervention: Stable Isotope Amino Acid Infusion
Description: Continuous infusion of L-\[1-13C\]leucine (0.13 μmol⋅kg⋅min) and L-\[ring- 2H5\]phenylalanine (0.05 μmol⋅kg⋅min)

Intervention type: OTHER
Intervention: Stable Isotope Amino Acid Infusion
Description: Continuous infusion of L-\[1-13C\]leucine (0.13 μmol⋅kg⋅min) and L-\[ring- 2H5\]phenylalanine (0.05 μmol⋅kg⋅min)
Study: NCT00799058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapivirine 4789
Description: dapivirine gel 4789, 0.05%, 2.5g applied once daily
Study: NCT02986620

Intervention type: GENETIC
Intervention: IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
Description: Observation of the test result.
Study: NCT04216875

Intervention type: PROCEDURE
Intervention: Best Practice Diabetes Management in Primary Care
Description: Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
Study: NCT00799058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapivirine gel 4759
Description: dapivirine gel 4759, 0.05%, 2.5g applied once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug placebo
Description: HEC-based universal placebo gel, 2.5g applied once daily
Study: NCT00985244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
Study: NCT03488082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI
Description: saccadic adaptation (target presentations, with or without target jump) during fMRI exam
Study: NCT02060812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group I, SSNB & ANB
Description: Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group II, SSNB alone
Description: This is same as the Group I, SSNB \& ANB, but ANB was performed with placebo(10mL normal saline).
Study: NCT04620408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
Study: NCT03159247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eyeGuide
Description: The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
Study: NCT01811472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: LCQ908 5 mg, 10 mg, 20 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: LCQ908 5 mg, 10 mg, 20 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
Study: NCT01461772

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
Study: NCT04350411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional diathermy
Description: Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade™
Description: Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
Study: NCT02371655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: A low-fibre diet for three days before the examination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faecal Tagging
Description: Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faecal Tagging
Description: Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bowel cleansing
Description: Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel cleansing
Description: Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT colonography
Description: CT Examination of the colon aimed to detect polyps and cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT colonography
Description: CT Examination of the colon aimed to detect polyps and cancer
Study: NCT02898376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin-oriented spa care
Description: standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 400 mg bid during at least 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400 mg bid during at least 6 months
Study: NCT00315016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosinopril
Description: doubling of fosinopril dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (double dummy)
Study: NCT01461772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
Study: NCT00924911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: Four different formulations of 1000mg of GSK1322322
Study: NCT02097654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SENATOR software generated pharmacotherapy advice report.
Study: NCT04519697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT02578186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine Hydrochloride
Description: 30 mL at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mL at bedtime
Study: NCT03323801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid
Description: Accutane is used for the treatment of severe acne
Study: NCT02021955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guideline treatment recommendations
Description: Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
Study: NCT02302391

Intervention type: OTHER
Intervention: PK analysis
Description: Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
Study: NCT04623840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tadalafil 5Mg Tab + continuous and interval exercise
Description: (n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5Mg Tab
Description: (n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
Study: NCT02549131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomizing to Suture or Staple closure of Cesarean section
Description: Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomizing to Suture or Staple closure of Cesarean section
Description: Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
Study: NCT03659071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire VSP-A
Description: VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire VSP-A
Description: VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
Study: NCT03908814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Human Anti-PD-L1 Antibody Injection (LDP)
Description: Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
Study: NCT01523509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiographic contrast agent. Sodium Iodide.
Description: Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
Study: NCT03405818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavaborole 5% Topical Solution
Description: topical solution for application to toenails
Study: NCT04317989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: 1. Implementing evidence-based protocols and the use of clinical algorithms (for screening, counseling, referral, and MAT) to engage the entire clinical team in a high standard delivery of care.~2. Promoting a strong use of decision support tools and templates to support the practice workflow.~3. Optimizing the use of the electronic health record (EHR) to pull clinical data on a monthly basis to guide the change process.~4. Developing patient registries (e.g., for those identified to have AUD) to identify needed care~5. Proactive, team-based care with assigned roles and responsibilities to prepare the clinical team to develop needed care and engage patients throughout the entire visit process.~6. Enhancing the understanding of available counseling and referral resources to ensure that practices are confident that they have appropriate evidence-based intervention options.
Study: NCT01834352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Walnut Protein Flour
Description: Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oat flour
Description: Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
Study: NCT02237755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.